Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Awakn Life Sciences Corp (OP: AWKNF )

0.1100 -0.0175 (-13.73%)
Streaming Delayed Price Updated: 1:18 PM EDT, May 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,548
Open 0.1275
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1275
Today's Range 0.1100 - 0.1275
52wk Range 0.0422 - 0.2600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga

Performance

YTD
-0.45%
-0.45%
1 Month
-19.94%
-19.94%
3 Month
+2.33%
+2.33%
6 Month
+74.60%
+74.60%
1 Year
-48.50%
-48.50%

More News

Read More
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Via Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
Via Benzinga
Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
Via Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
Via Benzinga
U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Via Benzinga
Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
Via Benzinga
Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
Via Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
Via Benzinga
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
Via Benzinga
Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
Via Benzinga
Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
Via Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Via Benzinga
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
Via Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Via Benzinga
Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
Via Benzinga
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Via Benzinga
Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.